134 related articles for article (PubMed ID: 22204346)
1. Polysaccharide-K (PSK) in cancer--old story, new possibilities?
Sun C; Rosendahl AH; Wang XD; Wu DQ; Andersson R
Curr Med Chem; 2012; 19(5):757-62. PubMed ID: 22204346
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.
Fisher M; Yang LX
Anticancer Res; 2002; 22(3):1737-54. PubMed ID: 12168863
[TBL] [Abstract][Full Text] [Related]
3. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review.
Fritz H; Kennedy DA; Ishii M; Fergusson D; Fernandes R; Cooley K; Seely D
Integr Cancer Ther; 2015 May; 14(3):201-11. PubMed ID: 25784670
[TBL] [Abstract][Full Text] [Related]
4. Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells.
Rosendahl AH; Sun C; Wu D; Andersson R
Pancreatology; 2012; 12(6):467-74. PubMed ID: 23217280
[TBL] [Abstract][Full Text] [Related]
5. The use of mushroom glucans and proteoglycans in cancer treatment.
Kidd PM
Altern Med Rev; 2000 Feb; 5(1):4-27. PubMed ID: 10696116
[TBL] [Abstract][Full Text] [Related]
6. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.
Lu H; Yang Y; Gad E; Wenner CA; Chang A; Larson ER; Dang Y; Martzen M; Standish LJ; Disis ML
Clin Cancer Res; 2011 Jan; 17(1):67-76. PubMed ID: 21068144
[TBL] [Abstract][Full Text] [Related]
7. Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells.
Yoshikawa R; Yanagi H; Hashimoto-Tamaoki T; Morinaga T; Nakano Y; Noda M; Fujiwara Y; Okamura H; Yamamura T
Oncol Rep; 2004 Dec; 12(6):1287-93. PubMed ID: 15547752
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer.
Tanaka H; Muguruma K; Ohira M; Kubo N; Yamashita Y; Maeda K; Sawada T; Hirakawa K
Anticancer Res; 2012 Aug; 32(8):3427-33. PubMed ID: 22843926
[TBL] [Abstract][Full Text] [Related]
9. [Immunomodulatory and antitumor properties of polysaccharide peptide (PSP)].
Piotrowski J; Jędrzejewski T; Kozak W
Postepy Hig Med Dosw (Online); 2015 Jan; 69():91-7. PubMed ID: 25614677
[TBL] [Abstract][Full Text] [Related]
10. The effect and distribution of a protein-bound polysaccharide preparation, PSK (Krestin), intratumorally injected prior to surgery into gastric cancer patients.
Tomochika H; Gouchi A; Okanobu K; Sasaki A; Fuchimoto S; Orita K
Acta Med Okayama; 1989 Oct; 43(5):289-97. PubMed ID: 2610006
[TBL] [Abstract][Full Text] [Related]
11. Krestin (PSK).
Tsukagoshi S; Hashimoto Y; Fujii G; Kobayashi H; Nomoto K; Orita K
Cancer Treat Rev; 1984 Jun; 11(2):131-55. PubMed ID: 6238674
[TBL] [Abstract][Full Text] [Related]
12. Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.
Maehara Y; Tsujitani S; Saeki H; Oki E; Yoshinaga K; Emi Y; Morita M; Kohnoe S; Kakeji Y; Yano T; Baba H
Surg Today; 2012 Jan; 42(1):8-28. PubMed ID: 22139128
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
[TBL] [Abstract][Full Text] [Related]
14. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
Mizutani Y; Yoshida O
J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
[TBL] [Abstract][Full Text] [Related]
15. In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer.
Sugimachi K; Maehara Y; Kusumoto T; Okamura T; Korenaga D; Kohnoe S; Baba H; Anai H
Anticancer Res; 1995; 15(5B):2175-9. PubMed ID: 8572620
[TBL] [Abstract][Full Text] [Related]
16. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer.
Torisu M; Hayashi Y; Ishimitsu T; Fujimura T; Iwasaki K; Katano M; Yamamoto H; Kimura Y; Takesue M; Kondo M
Cancer Immunol Immunother; 1990; 31(5):261-8. PubMed ID: 2198088
[TBL] [Abstract][Full Text] [Related]
17. Polysaccharide-K (PSK) may suppress surgical stress-induced metastasis in rat colon cancer.
Tamagawa K; Horiuchi T; Wada T; Bannai K; Ando T
Langenbecks Arch Surg; 2012 Mar; 397(3):475-80. PubMed ID: 22207390
[TBL] [Abstract][Full Text] [Related]
18. Anti-protein-bound polysaccharide-K monoclonal antibody binds the active structure and neutralizes direct antitumor action of the compound.
Hoshi H; Saito H; Iijima H; Uchida M; Wada T; Ito G; Tanaka H; Sawada T; Hirakawa K
Oncol Rep; 2011 Apr; 25(4):905-13. PubMed ID: 21249323
[TBL] [Abstract][Full Text] [Related]
19. [Effect of PSK on recurrence of stage II/III gastric cancer].
Tanaka H; Muguruma K; Kubo N; Amano R; Noda E; Yamada N; Yashiro M; Maeda K; Sawada T; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2258-60. PubMed ID: 21224540
[TBL] [Abstract][Full Text] [Related]
20. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide.
Kato M; Hirose K; Hakozaki M; Ohno M; Saito Y; Izutani R; Noguchi J; Hori Y; Okumoto S; Kuroda D
Cancer Immunol Immunother; 1995 Mar; 40(3):152-6. PubMed ID: 7728773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
